Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
After a conference lacking the wow factor, biotech winners and losers emerge.
Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.
If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.